Mental DailyMental Daily
  • Clinical
  • Health
  • I/O
  • Cybernetic
  • Social
  • More
    • Opinion
    • The Discussion
    • My Bookmarks
Aa
Mental Daily
Aa
  • Clinical
  • Health
  • I/O
  • Cybernetic
  • Social
  • Opinion
Search
  • Clinical
  • Health
  • I/O
  • Cybernetic
  • Social
  • More
    • Opinion
    • The Discussion
    • My Bookmarks
Follow US
  • Twitter
  • Facebook
  • Instagram
  • Inc. Profile
  • Google Play Store
© 2022 - Mental Daily. All Rights Reserved.
Clinical

New experimental drug may impede amyloid pathology associated with Alzheimer’s disease

Staff Writer
Staff Writer 1 year ago
Updated 2021/05/12 at 6:18 PM
Share
SHARE

Pathological hallmarks of Alzheimer’s disease may be impeded by the use of a new experimental drug developed by researchers at the University of California, San Diego, according to their recent findings.

Publicized in the Journal of Experimental Medicine, the American research team conducted tests on rodents using the novel γ-secretase modulators or GSMs to establish its efficiency.

Based on their series of tests, low doses of the GSM resulted in the termination of Aβ42 production among the rodents. The drug was effective enough to reduce the production by nearly 70 percent, with its administration incapable of leading to any toxic side effects.

The drug was tested before and after the formation of amyloid plaques. Plaque formation and subsequent inflammation associated with Alzheimer’s disease were reduced significantly by the drug, the findings showed.

“In this study, we have pharmacologically characterized a potent GSM that, based on its preclinical attributes, appears to equal or exceed the potency of any previously tested GSMs,” said one co-author of the study in a news release.

“Future clinical trials will determine whether this promising GSM is safe in humans and could be used to effectively treat or prevent Alzheimer’s disease.”

Photo: NSF

You Might Also Like

Study finds no structural brain change during mindfulness-based stress training

Study finds diet may be a contributing factor in ADHD symptoms associated in children

New research claims COVID-19 contagion may raise the risk of neurodegenerative disorder

ALS experimental drug NU-9 more efficacious than existing FDA-approved drugs

How adolescent binge drinking can significantly affect brain function

TAGGED: amyloid pathology, Alzheimer's disease, cognition, dementia
Staff Writer March 2, 2021
Share this Article
Facebook Twitter Whatsapp Whatsapp Email Print
Previous Article Patients with obstructive sleep apnea may be more likely to suffer from cognitive decline
Next Article Excessive preoccupation with screen time may increase the risk of binge-eating disorder in young children

Recommended

Clinical

Study finds no structural brain change during mindfulness-based stress training

1 Min Read
Clinical

Study finds diet may be a contributing factor in ADHD symptoms associated in children

1 Min Read
Clinical

New research claims COVID-19 contagion may raise the risk of neurodegenerative disorder

1 Min Read
Clinical

ALS experimental drug NU-9 more efficacious than existing FDA-approved drugs

1 Min Read
//

We are a trusted online source for research news and resources on all aspects of the mind and human behavior.

Verticals

  • Clinical
  • Health
  • Social
  • I/O
  • Opinion

Social

  • Twitter
  • Facebook
  • Instagram
  • Inc. Profile
  • Google Play Store

Links

  • About
  • Contact
  • Terms & Conditions
  • Privacy Policy
Follow US

© 2022 Mental Daily. All Rights Reserved.

  • Twitter
  • Facebook
  • Instagram
  • Inc. Profile
  • Google Play Store

Removed from reading list

Undo
Welcome Back!

Sign in to your account

Lost your password?